TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05618197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: \~3x per week of 1 h hot water immersion (to the clavicle, @40°C, rectal temperature \~38.5°C and \<39°C) sessions over a period of 6 weeks.
Study: NCT06438458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postural change from supine to sitting
Description: Patients go from supine to sitting position in bed (passive)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mobilization to a chair
Description: Patients go from the bed to sitting in a chair (active)
Study: NCT05373472

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo on Day 0 and Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses of placebo on Day 0 and Day 21
Study: NCT03886402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: Treatment of erectile dysfunction with the subjects own cells
Study: NCT06004505

Intervention type: OTHER
Group type: OTHER
Intervention: Vestibular Rehabilitation
Description: The patients received vestibular rehabilitation treatment in 4 sessions at 15-day intervals and applied the given exercise programs as home exercise in the form of 10 repetitions, 3 times a day. The exercises were performed sitting, standing and walking, respectively. Balance exercises were developed by changing the support area, support surface and arm positions. When they come to each session, the exercise programs are according to the patient's condition; alternating standing and walking forward, backward, tandem and semitandem positions.
Study: NCT05566561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramadol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, and 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study: NCT04753619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Oral Tablet
Description: * NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. \[ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days\]~* If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Study: NCT05130294

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CARDIO®
Description: CARDIO® is manufactured according to Good Manufacturing Practices for food facilities complying with the Hazard Analysis and Critical Control Points (HACCP) principles.~The product is intended for use in manufacturing of human food products and human consumption, including food supplements, and have been Generally Recognized as Safe (self-affirmed GRAS). The fresh unrefined salmon oil is produced by Hofseth Biocare ASA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCT oil
Study: NCT06426173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training Program
Description: The resistance training program will be individualized and divided into four stages of increasing complexity. It will be conducted for approximately 40 minutes per day, three times a week, for 12 weeks, under supervision. Each patient will begin the program at the stage corresponding to their functional capacity. The resistance load will be set at 50% of the maximum resistance (1RM) obtained in the initial assessment. Throughout all stages of the exercise program, the target intensity will range from light (≤ 12) to moderate (≤ 15) on the Borg scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Group
Description: Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Group
Description: Patients will receive the standard treatment provided by the hospital inpatient unit, which includes guidance on reducing sedentary time, encouragement to walk, and performance of active and breathing exercises when necessary.
Study: NCT04436978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30-day DAPT
Description: DAPT (aspirin + P2Y12 inhibitor) during the first 30 days following PCI. After 30 days, all patients will be treated with edoxaban and a P2Y12 inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-directed therapy
Description: Guideline-directed therapy (edoxaban + P2Y12 inhibitor, aspirin limited to in-hospital use or up to 30 days in selected high-risk patients)
Study: NCT04764006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib(250mg ,qd,po)+Sintilimab(200mg,q3w,iv),21 days for a cycle.The curative effect was evaluated every 8 weeks.
Study: NCT06073535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction of mandibular third molar
Description: After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle.~An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-PRF
Description: 20 ml of venous blood will be drawn from the ante-cubital vein of all patients and collected in 2 plastic tubes (Vacutainer, Becton\& Dickinson, Rutherford, NJ) containing no anticoagulant or gelling agent. The tubes will be placed in a centrifuge (DUO Centrifuge, Nice, France) at 700 round per minute for 3 min, at the end of which time the blood will be separated into 2 fractions: the layer of injectable liquid i-PRF, which is more superficial, and the layer of red blood cells, in the deep part. From each tube, i-PRF will be withdrawn using a sterile syringe and it will be infiltrated into the lesion.
Study: NCT04936828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study: NCT04883970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 124I-18B10(10L) PET/CT
Description: Study participants will undergo 124I-18B10(10L) PET/CT scans
Study: NCT05426304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Agomelatine
Description: agomelatine 25 mg/day for 180 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: placebo 25 mg/day for 180 days
Study: NCT05000970

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood pressure cuff PLUS tablet
Description: all arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure cuff PLUS tablet
Description: all arms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood pressure cuff PLUS tablet
Description: all arms

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Consult
Description: Telehealth consult with an RN

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Consult
Description: Telehealth consult with an RN
Study: NCT06301503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USG Guided Combined LPB-SNB with Isobaric Bupivacaine
Description: Local anesthetic infiltration of 2% lidocaine (3ml) along with injection anaesthetic agent consisting of isobaric bupivacaine 0.25% (20 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Local anesthetic infiltration of 2% lidocaine (3ml)
Study: NCT06300424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: almonertinib
Description: 110mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, d1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 135 mg/m2, d1,d8 every 3 weeks
Study: NCT06031012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine combined with thalidomide
Description: Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glutamine alone
Description: Patients received glutamine alone from the beginning of radiotherapy to one week after radiotherapy.
Study: NCT01484353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coronary Health Improvement Project Program
Description: The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
Study: NCT06518668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKX019
Description: NKX019 is an investigational allogeneic CD19-Directed CAR NK. NKX019 will be administered at a dose of 1 × 109 CAR NK cells (dose normalized for weight for subjects ≤ 50 kg) administered IV.
Study: NCT04717102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 MAC desflurane
Description: Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75 MAC desflurane
Description: Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 MAC desflurane
Description: On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Description: On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.
Study: NCT06091852

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intrinsically labelled milk protein
Description: 20 grams of protein dissolved in 500 mL of water
Study: NCT05855083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: narsoplimab
Description: Treatment with narsoplimab 4 mg/kg will be administered
Study: NCT06518668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide LD
Description: Cy dose of 1 g/m2 administered IV over 30 to 60 minutes for the purpose of Lymphodepletion Therapy. Cyclophosphamide will help prepare your body to receive the treatment by decreasing the cells from your immune system to make space for the NKX019 cells.~(non-experimental)
Study: NCT04542733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus will be given with tacrolimus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: reduced dose tacrolimus
Description: Reduced dose tacrolimus will be given with or without leflunomide
Study: NCT04775654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blackcurrant
Description: Two capsules containing 455mg of CurrantCraft 11% black currant extract.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules containing an inert material.
Study: NCT05572060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patient screening will be done using SOFA scoring and NEWS Supplemental oxygen will be supplied. Intubation and mechanical ventilation may be required Venous access will be established.CBC, chemistries, liver function tests,coagulation studies ,Peripheral blood cultures, urinalysis, microbiological cultures from suspected sources (eg, sputum, urine,etc),(ABG) and serum lactate will be obtained Crystalloids will be given at 30 mL/kg, started by one hour and completed within three hours Empiric antibiotic therapy is targeted at the suspected organism(s) In patients with lactic acidosis and severe acidemia, Sodium bicarbonate will be used to maintain the arterial pH above 7.15 In patients having persistent hypoperfusion vasopressors will be added Evaluation of volume status will be done using straight leg raising test and ultrasound guided IVC collapsibility index Plasma rennin, serum lactate and IL6 concentrations will be measured on admission and at one week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized protocol
Description: standardized protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized protocol
Description: standardized protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized protocol
Description: standardized protocol
Study: NCT04775992

Intervention type: OTHER
Intervention: gabapentoids
Description: Preemptive analgesia
Study: NCT05791682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealant, Fissure
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealant, Fissure
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealant, Fissure
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sealant, Fissure
Description: FISSURIT FX- MICROFILLED RESIN SEALANT WITH 55% FILLER GRANDIOSEAL- NANOFILLED RESIN SEALANT WITH 70% FILLER TE-ECONOM- FLOW -FLOWABLE COMPOSITE AS SEALANT CLINPRO TM- UNFILLED RESIN SEALANT
Study: NCT04823962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF + hydrogel
Description: The active substance: molgramostim (rhGM-CSF)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo hydrogel
Description: Placebo hydrogel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Compression therapy and neutral dressings

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Compression therapy and neutral dressings
Study: NCT05456711

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
Description: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
Description: ultrasonographic measurement for femoral cartilage thickness VAS for pain severity WOMAC for functionality
Study: NCT05484453

Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Eye Examination by Ophthalmologist
Description: complete eye examination (gold standard) including cover test, biomicroscopy and cycloplegic refraction with retinoscopy, performed by an ophthalmologist.
Study: NCT05544565

Intervention type: DRUG
Group type: OTHER
Intervention: IV Antibacterial Agents
Description: Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Antibacterial Agents
Description: Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days. .

Intervention type: DRUG
Group type: OTHER
Intervention: Orally antibacterial agents
Description: Cotrimoxazole (sulfamethoxazole/trimethoprime) 30mg/kg/day (2 divided doses) OR Cefixime 8mg/kg/day (2 divided doses) during 7 days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fecal/Rectal Swab
Description: Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal/Rectal Swab
Description: Collected by the nurse or the physician (D0,D3,D14) (and parents for D45), either by a rectal swab, either by fecal swab (dip of the swab in fresh stools \< 4 hours, which will occur frequently in our population of children aged 1 month to 3 years, and will in particular be possible for hospitalized children) using a FecalSwabTM, that contains a transport medium.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCT assay
Description: Dosage of procalcitonin (if not performed in standard care) at D0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCT assay
Description: Dosage of procalcitonin (if not performed in standard care) at D0

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal scintigraphy
Description: A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal scintigraphy
Description: A DMSA scintigraphy (99mTc-DMSA) will be performed at 6 months (± 15 days) for evaluation of the kidney growth and renal scars
Study: NCT05461118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental:Treatment group
Description: Osteotomy surgical planning to be done using intraoperative mixed reality augmentation of a commercially available navigation platform.
Study: NCT05051501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics C2P
Description: Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics C2P
Description: Probiotics will supplement normal diet. Unlike other products available on the market, which are usually of bovine origin, our probiotic has been manufactured using human-stemmed lines. The supplements are composed of a mixture of naturally occurring human gut bacteria.